Seasonal Influenza Vaccines - US Drug Forecast and In-Depth Industrial and Market studies Analysis to 2025
Albany, New York, Feb 02, 2017
"Seasonal
Influenza Vaccines - US Drug Forecast and Market Analysis to 2025"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Influenza,
often referred to as the flu, is an acute infection caused by one of
the three closely related viruses, designated as influenza Type A, B,
and C. The infections rapid onset and potential for high morbidity
and mortality, particularly in high-risk patient populations such as
the elderly and young children, make prompt and effective treatment
with antiviral medication very difficult. For these reasons,
prophylactic vaccination is the preferred intervention for seasonal
influenza.
The
US will experience solid growth in seasonal influenza vaccine sales
during the forecast period, and this growth will be driven by a
significant shift in the market share distribution of the different
vaccine types. The US market will experience the largest nominal
change of any country in the 7MM.
*
Scope
-
Overview of Seasonal Influenza Vaccines including epidemiology,
etiology, symptoms, diagnosis, pathology and treatment guidelines as
well as an overview on the competitive landscape.
-
Detailed information on the key drugs in the US including product
description, safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in the US from 2015-2025.
-
Analysis of the impact of key events as well the drivers and
restraints affecting the US Seasonal Influenza Vaccines market.
*
Reasons to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for Seasonal Influenza Vaccines.
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2015-2025 in the US.
*
Table of Contents
1
Table of Contents 2
1.1
List of Tables 6
1.2
List of Figures 10
2
Introduction 11
2.1
Catalyst 11
2.2
Related Reports 12
2.3
Upcoming Related Reports 12
3
Disease Overview 13
3.1
Etiology and Pathophysiology 13
3.1.1
Etiology 13
3.1.2
Pathophysiology 18
3.1.3
Symptoms and Prognosis 19
4
Disease Management 21
4.1
Seasonal Influenza Immunization Policy 21
4.1.1
Immunization Recommendations and Most Frequently Administered
Seasonal Influenza Vaccines 22
4.2
US 24
4.2.1
Influenza Immunization Recommendations and Policies 25
4.2.2
Clinical Practice 28
5
Competitive Assessment 30
5.1
Overview 30
5.2
Product Profiles - Major Brands, Inactivated Vaccines 32
5.2.1
Fluzone Quadrivalent 32
5.2.2
Fluzone High-Dose 38
5.2.3
Fluzone Intradermal 45
5.2.4
Vaxigrip 53
5.2.5
Fluarix Tetra 59
5.2.6
Fluvirin 66
5.2.7
Afluria 71
5.2.8
Agrippal 77
5.3
Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted) 81
5.3.1
Fluad 81
5.4
Product Profiles - Major Brands, Live-Attenuated Vaccines 88
5.4.1
FluMist Quadrivalent 88
5.5
Product Profiles - Major Brands, Cell Cultured Vaccines 96
5.5.1
Flublok 96
5.5.2
Flucelvax 103
5.6
Other Seasonal Influenza Vaccines 110
5.6.1
Influvac 110
5.6.2
Minor Brands 112
6
Unmet Needs and Opportunity Analysis 113
6.1
Overview 113
6.2
Higher Level of Public Awareness and Positive Perception of Influenza
Vaccines 117
6.2.1
Unmet Need 117
6.2.2
Gap Analysis 118
6.2.3
Opportunity 121
6.3
Immunization Policies Targeting Children and Adolescents 122
6.3.1
Unmet Need 122
6.3.2
Gap Analysis 123
Comments
Post a Comment